Abstract
Purpose: To evaluate the effect of intra-vitreal bevacizumab in macular edema
caused by branch retinal vein occlusion.
Study Design: Interrupted time series study.
Place and Duration of Study: Department of Ophthalmology Hayatabad
Medical Complex, Peshawar and department of Ophthalmology Lady Reading
Hospital Peshawar from 1st July 2016 to 31st December 2016.
Material and Methods: There were 60 patients included in the study. All
patients with macular edema due to BRVO visible clinically and evident on SDOCT and visual acuity of less than 6/9 were included in the study. Patients who
used other intra-vitreal drug for macular edema, those with surgery in the same
eye and those with macular laser for macular edema were excluded from the
study. All patients were given intra-vitreal 0.05 ml bevacizumab injection every
month for 6 months. After 6 months OCT was repeated. At each monthly visit
VA was measured and fundoscopy was done. Follow up of all patients was at
six months.
Results: Our study included 60 patients with mean age of 54.42 ± 9.19 years.
The mean baseline central macular thickness was 427.06 µ with SD ± 63.54 µ.
After 6 months significant improvement in visual acuity was documented. Also
marked reduction in central macular thickness was noted after six months with
mean of 327.44 µ with SD ± 55.55 µ.
Conclusion: Intra-vitreal bevacizumab is an effective treatment for macular
edema caused by BRVO in terms of both anatomic and visual improvement
Imran Ahmad, Mubashir Rehman, Mir Ali Shah, Irfan Aslam Khattak. (2019) Effect of Intravitreal Bevacizumab in Macular Edema Caused by Branch Retinal Vein Occlusion, Pakistan Journal of Ophthalmology, Volume 35, Issue 1.
-
Views
907 -
Downloads
84
